Furthermore, mice treated with GITRL blockers or GITR-deficient mice exhibited reduced inflammatory symptoms in models of lung and gut inflammation, pancreatitis, diabetes, allograft rejection, spinal cord injury and other diseases [33–36]. This evidence concerns the gene TNFSF18 and pancreatitis.